Photo Release -- Hemispherx Biopharma Posts Photographs of the Ampligen Facility in New Brunswick, New Jersey
27 août 2015 08h30 HE
|
AIM ImmunoTech Inc.
NEW BRUNSWICK, N.J., Aug. 27, 2015 (GLOBE NEWSWIRE) -- Hemispherx Biopharma (NYSE MKT:HEB) recently hosted a Stockholder Open House in their manufacturing facility in New Brunswick, NJ. During the...
Hemispherx Biopharma's Judgment Unanimously Affirmed Against Cato Capital
26 août 2015 10h00 HE
|
AIM ImmunoTech Inc.
WILMINGTON, Del., Aug. 26, 2015 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE Amex:HEB) (the "Company" or "Hemispherx") announced that on Friday the Third Circuit Court of Appeals upheld the...
Hemispherx Biopharma Reminder Regarding Stockholder Open House at Manufacturing and Research Facility in New Jersey
19 août 2015 08h30 HE
|
AIM ImmunoTech Inc.
PHILADELPHIA, Aug. 19, 2015 (GLOBE NEWSWIRE) -- As previously announced and provided in the proxy materials, the Management and the Board of Directors of Hemispherx Biopharma (NYSE MKT:HEB) will host...
Hemispherx Biopharma Extends Its Strategic Alliance With Armada Health Care for Alferon N Injection(R)
17 août 2015 08h30 HE
|
AIM ImmunoTech Inc.
PHILADELPHIA, Aug. 17, 2015 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE:HEB) (the "Company" or "Hemispherx"), announced that as the Company works toward the re-launch of Alferon N, it has...
Hemispherx Biopharma Board Appoints New President
13 août 2015 08h30 HE
|
AIM ImmunoTech Inc.
PHILADELPHIA, Aug. 13, 2015 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE MKT:HEB) (the "Company" or "Hemispherx") today announced that the Board has appointed Thomas Equels as the new...
Hemispherx Expands Its Collaboration With Emerge Health for the Commercialization of Alferon in Australia and New Zealand
11 août 2015 08h30 HE
|
AIM ImmunoTech Inc.
PHILADELPHIA, Aug. 11, 2015 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE MKT:HEB) (the "Company" or "Hemispherx"), reported today that it has executed an agreement with Emerge Health Pty Ltd....
Hemispherx Enters Into an Agreement With myTomorrows for an Early Access Program for Rintatolimod in Europe
10 août 2015 08h30 HE
|
AIM ImmunoTech Inc.
PHILADELPHIA, Aug. 10, 2015 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE MKT:HEB) (the "Company" or "Hemispherx"), reported today that it has executed an agreement with Impatients, N.V., a...
Hemispherx Biopharma to Host Stockholder Open House at Manufacturing and Research Facility in New Jersey
27 juil. 2015 08h30 HE
|
AIM ImmunoTech Inc.
PHILADELPHIA, July 27, 2015 (GLOBE NEWSWIRE) -- The Management and the Board of Directors of Hemispherx Biopharma (NYSE MKT:HEB) have announced that the company will host a Stockholder Open House at...
Hemispherx Biopharma Announces Final Approval of Securities Class Action Settlement
23 juil. 2015 08h30 HE
|
AIM ImmunoTech Inc.
PHILADELPHIA, July 23, 2015 (GLOBE NEWSWIRE) -- Hemispherx Biopharma (NYSE MKT:HEB) announced that the United States District Court for the Eastern District of Pennsylvania has issued an order...
Hemispherx Biopharma Europe N.V./S.A. Submits Application for Orphan Medicine Designation to the EMA for Alferon N Injection(R) for Treatment of Middle East Respiratory Syndrome (MERS)
15 juil. 2015 08h30 HE
|
AIM ImmunoTech Inc.
PHILADELPHIA, July 15, 2015 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE MKT:HEB) (the "Company" or "Hemispherx") announces that they have submitted an application for orphan drug designation...